Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Novartis Pharmaceuticals704 enrolled

Overview

This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.

Screening/Subject eligibility: Subjects with histologically confirmed cutaneous melanoma that was either unresectable or metastatic (Stages IIIC or IV), were screened for eligibility. Eligible subjects were BRAF V600E or V600K mutation positive. Subjects who had prior systemic anti-cancer treatment in the advanced or metastatic setting were not eligible although prior systemic treatment in the adjuvant setting was allowed. Randomization: A total of 704 subjects were randomized in a ratio of 1:1 to receive combination therapy (352 subjects) or vemurafenib treatment (352 subjects). Subjects were stratified by LDH level (\> the ULN versus =\< ULN) and BRAF mutation (V600E versus V600K). Study treatment: Dabrafenib and trametinib were administered orally at their recommended doses of 150 mg b.i.d. and 2.0 mg once daily, respectively. Subjects randomized in the combination therapy arm received both the agents. Subjects randomized in the vemurafenib arm received vemurafenib at the recommended dose of 960 mg orally b.i.d. Subjects in both the arms continued treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent. The protocol was amended on 07-Aug-2014 which allowed subjects who were still receiving vemurafenib to cross over to the dabrafenib and trametinib combination arm, including those subjects who were still receiving vemurafenib monotherapy treatment after disease progression. A washout period of a minimum of 7 days was considered prior to initiating dabrafenib in combination with trametinib. Subjects who experienced disease progression on the vemurafenib monotherapy arm, discontinued vemurafenib monotherapy, and subsequently received another anticancer therapy were ineligible for cross over to the dabrafenib and trametinib combination arm. Follow-up/Study closure: After study treatment discontinuation, subjects were followed for survival and disease progression as applicable. This study completed once all the subjects had at least the 5-years of follow-up.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

704

Conditions

Melanoma

Interventions

DabrafenibDRUG

Dabrafenib 150 mg twice daily orally

VemurafenibDRUG

Vemurafenib 960 mg twice daily orally

TrametinibDRUG

Trametinib 2 mg once daily orally

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * \>= 18 years of age * Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma * Measurable disease according to RECIST 1.1 * Women of childbearing potential with negative serum pregnancy test prior to randomisation * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate baseline organ function Key Exclusion Criteria: * Any prior use of a BRAF or MEK inhibitor * Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed * History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer) * Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed) * Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for \>= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for \>= 12 weeks, and are asymptomatic with no corticosteroid requirements for \>= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for \>= 4 weeks prior to randomisation * History or evidence of cardiovascular risk (LVEF \< LLN; QTcB \>= 480 msec; blood pressure or systolic \>=140 mmHg or diastolic \>= 90 mmHg which cannot be controlled by anti-hypertensive therapy) * History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

Locations (205)

Outcomes

Primary Outcomes

Overall Survival (OS)

Overall Survival (OS) was defined as the interval of time between the date of randomization and the date of death due to any cause. For patients who did not die, OS was censored at the date of last contact.

Time frame: From the date of randomization until date of death due to any cause (up to approximately 6 years)

Secondary Outcomes

Progression-Free Survival (PFS), as Assessed by the Investigator

Progression-free survival (PFS) was defined as the interval of time between the date of randomization and the first documented occurrence of disease progression or death due to any cause. PFS for investigator-assessed response was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.

Time frame: From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)

Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator

Overall response was defined as the percentage of confirmed responders (complete response \[CR\] + partial response \[PR\] per RECIST, Version 1.1) as summarized by Investigator assessment. CR was defined as the disappearance of all evidence of target lesions. PR was defined as at least a 30% reduction from Baseline in the sum of the longest diameter (LD) of all target lesions. Data were reported as those participants with measureable disease at Baseline.

Time frame: From randomization until the first documented complete response or partial response (up to approximately 6 years)

Duration of Response (DOR), as Assessed by the Investigator

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Birmingham, Alabama, United States

Novartis Investigative Site

Gilbert, Arizona, United States

Novartis Investigative Site

Beverly Hills, California, United States

Novartis Investigative Site

San Francisco, California, United States

Novartis Investigative Site

Vallejo, California, United States

Novartis Investigative Site

Aurora, Colorado, United States

Novartis Investigative Site

Jacksonville, Florida, United States

Novartis Investigative Site

Miami Beach, Florida, United States

Novartis Investigative Site

Orlando, Florida, United States

Novartis Investigative Site

Atlanta, Georgia, United States

...and 195 more locations